We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunohistochemical Stain Facilitates cHL Diagnosis

By LabMedica International staff writers
Posted on 11 Mar 2019
Remarkable efforts are underway to exploit classic Hodgkin lymphoma's (cHL) complex interplay of molecular alterations, loss of B-cell programming, and dependency of tumor microenvironment.

Tumor necrosis factor receptor superfamily member 9 or CD137 has been shown to induce proliferation and enhance the survival and function of T cells, natural killer cells, and dendritic cells. More...
Conceptually, agonistic anti-CD137 is categorized as a co-stimulatory immunotherapy with the potential to manipulate the tumor microenvironment and accentuate antitumor response.

Pathologists at the Naval Medical Center Portsmouth (Portsmouth, VA, USA) and The University of New Mexico School of Medicine (Albuquerque, NM, USA) constructed tissue microarrays from formalin-fixed, paraffin-embedded tissue including 42 cases of cHL, 33 cases of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), 16 cases of anaplastic large cell lymphoma, and seven cases of T-cell/histiocyte–rich large B-cell lymphoma. They validated anti-CD137 monoclonal BBK-2 clone, using protease retrieval and a dilution of 1:100.Tissue microarrays were then stained with CD137 as well as CD15, CD20, and CD30 and reviewed by two pathologists.

The scientists assigned positive staining if 20% or more of the malignant cells were positive regardless of strength of staining. Of the cHL cases, 76% were positive for CD137, 85% were positive for CD15, 100% were positive for CD30, and 13% were positive for CD20. Interestingly, CD137 was positive in all cHL cases where CD15 was negative. Conversely, CD15 was positive in 88% of cHL cases that were negative for CD137. Furthermore, CD137 was positive in 6% of NLPHL cases, 38% of anaplastic large cell lymphoma cases, and in none of the T-cell/histiocyte–rich large B-cell lymphoma cases.

The authors concluded that, although CD137 is not specific for cHL, it has utility in the immunohistochemistry (IHC) evaluation for cHL, in particular when the morphologic distinction with NLPHL is challenging. Additionally, it is easy to interpret, with minimal nonspecific background staining. Lastly, CD137 expression has been identified in several solid and hematopoietic neoplasms, and determination of this expression via IHC may prove to be a valuable biomarker of response to CD137 immunotherapy. The study was published in the March 2019 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Naval Medical Center Portsmouth
University of New Mexico School of Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.